With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
We are looking for an experienced highly motivated in vitro toxicologist to join a growing team responsible for leading the safety studies of Benevolent’s drug discovery and development portfolio. This is a great opportunity to work on a broad range of disease indications, you will have continuous oversight of programmes from validation to the clinic and gain experience managing a variety of outsourcing partners. We will provide the development and learning opportunities for you to progress your career into non-clinical safety project management, moving out of the lab into a more strategic and influential position. You will work with industry leaders in DMPK, chemistry and in vitro and in vivo pharmacology and your decisions and impact on these projects will have a tangible effect on the progression of clinical candidates.
With hybrid working from home and our London offices, you will be a core member of drug discovery project teams, working as the safety point of contact to progress programs from early discovery to the clinic.
Nice to haves
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email firstname.lastname@example.org. Thank you.